Innovative TCM Ercha Shangqing Wan approved for marketing

Recently, the Category 1.1 innovative traditional Chinese medicine (TCM) Ercha Shangqing Wan of Hubei Qijin Pharmaceutical Co Ltd was approved for marketing by China's National Medical Products Administration.

Randomized, double-blinded and placebo-controlled multicenter clinical trials had been conducted to evaluate the safety and efficacy of the medicine. The results showed that the group receiving the experimental medicine outperformed the placebo group in indicators of target ulcer healing rate, overall ulcer healing rate, overall ulcer healing time, and target ulcer healing time.

This medication, with its properties of clearing heat, detoxifying the body, healing aphtha and relieving pain, is intended for the treatment of mild recurrent upper-jiao heat syndrome in patients with aphthous ulcers.

The approval of this medical product provides another treatment option for patients with oral ulcers.

Note: In TCM, the concept upper-jiao, one of the three divisions of the body's energy, refers to the area of the body above the diaphragm, including the chest, lungs, heart, throat, head, and sensory organs.